Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4866 - Cancer-associated fibroblasts-derived VEGFA mediates the migration of gastric cancer cells through VEGFR1

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

xiaoxun Wang

Citation

Annals of Oncology (2018) 29 (suppl_8): viii1-viii13. 10.1093/annonc/mdy268

Authors

X. Wang1, X. Che2, Y. Fan2, M. Bai2, X. Qu2

Author affiliations

  • 1 The Department Of Medical Oncology, The first hospital of China medical university, 110001 - Shenyang/CN
  • 2 Medical Oncology, the first hospital of china medical university, shenyang/CN
More

Resources

Abstract 4866

Background

Cancer-associated fibroblasts (CAFs) are major components of the tumor stroma and regulators of tumor progression. CAFs are also involved in the intraperitoneal dissemination of gastric cancer cells. However, the molecular mechanism by which CAFs promote gastric cancer peritoneal dissemination should be further explored.

Methods

1. Cell migration ability was measured using Transwell assay. 2. Protein expression was analyzed by western blot. 3. Mouse model detects peritoneal metastasis of gastric cancer cells. 4. Affymetrix scanner 3000 was used to analyse the microarray genome-wide expression. 5. Statistical analysis. All values are expressed as means ± SD. The differences of the results between two groups were evaluated by Student’s t-test. P<0.05 was considered to be statistically significant.

Results

In our study, we found CAFs enhance the migration of gastric cancer cells through the expression of VEGFA. While VEGFA neutralizing antibody bevacizumab markedly attenuated these CAFs-induced phenotypes in gastric cancer cells. Moreover, VEGFA enhances the gastric cancer cells' ability to diffuse and metastasize in the peritoneum. And the Bevacizumab could inhibit peritoneal metastatic nodules. We further found the migration of MGC-803 was increased with VEGFA stimulation, mainly through VEGFR1 but not VEGFR2.

Conclusions

Taken together, these results revealed that the activation of VEGFR1 by CAFs-derived VEGFA enhances the migration of gastric cancer cells. And VEGFA enhances the peritoneal metastasis capacity of gastric cancer cells. Our results suggested that inhibition of VEGFA and its receptor VEGFR1 to control downstream signaling may provide a promising therapeutic target for the treatment of tumors.

Clinical trial identification

Legal entity responsible for the study

Academic Group.

Funding

National Natural Science of Foundation.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings